Please check your internet connection and try again.
# Walethimide bromide (Valethamate bromide)
## Overview
Walethimide bromide is a quaternary ammonium anticholinergic agent with antispasmodic and ganglion-blocking properties. It acts primarily by inhibiting the action of acetylcholine at muscarinic receptors in smooth muscle, leading to relaxation of the gastrointestinal, biliary, and urinary tracts.
## Primary Indications
* Adjunctive treatment for gastrointestinal spasms.
* Biliary colic and spasms of the genitourinary tract.
* Historically used in some regions for cervical dilation during labor (off-label use; declining status due to availability of more selective agents).
## Adult Dosing
* **Oral:** 10 mg to 20 mg taken 3 to 4 times daily.
* **Intramuscular/Intravenous:** 8 mg to 16 mg, to be administered as needed.
* **Maximum Dose:** Do not exceed 80 mg in a 24-hour period.
## Pediatric Dosing
* **Safety and Efficacy:** Not well-established. Use is clinical judgment-based and generally avoided. If necessary, dosing should be strictly weight-based (e.g., 0.1–0.2 mg/kg per dose) but must be verified against local institutional protocols.
## Dose Adjustments
* **Renal Impairment:** Use with caution; clearance of quaternary ammonium compounds may be reduced. Monitor for prolonged anticholinergic effects.
* **Hepatic Impairment:** No specific guidelines; use with caution.
* **Geriatric Patients:** Increased susceptibility to anticholinergic side effects (e.g., urinary retention, confusion, constipation). Start at the lower end of the dosing range.
## Contraindications
* Hypersensitivity to the drug.
* Narrow-angle glaucoma.
* Prostatic hypertrophy or bladder neck obstruction.
* Pyloric stenosis or paralytic ileus.
* Myasthenia gravis.
* Tachycardia due to thyrotoxicosis or cardiac insufficiency.
## Adverse Effects
* **Common:** Dry mouth, blurred vision, tachycardia, constipation, and urinary retention.
* **Serious:** Paradoxical agitation (especially in elderly), arrhythmias, and acute angle-closure glaucoma episodes.
## Key Drug Interactions
* **Antimuscarinics/Anticholinergics:** Additive toxicity (e.g., diphenhydramine, tricyclic antidepressants, antipsychotics).
* **Potassium Chloride:** Increased risk of gastrointestinal mucosal injury with solid oral dosage forms of potassium.
* **Metoclopramide:** Antagonizes the prokinetic effects of metoclopramide.
## Monitoring
* Monitor heart rate for excessive tachycardia.
* Assess for bowel function and urinary output.
* Observe for cognitive changes or delirium in elderly patients.
## Clinical Pearls
* Quaternary ammonium structure limits central nervous system penetration compared to tertiary amines (like atropine), theoretically reducing CNS side effects; however, central toxicity can still occur at high doses.
* There is significant clinical uncertainty regarding its current status in obstetric practice; use for cervical dilation is controversial and often superseded by site-specific agents.
* Always verify if the product is locally stocked or if alternative anticholinergics (e.g., hyoscine butylbromide) are preferred.
***
**Disclaimer:** This information is for educational purposes only. Drug dosing, availability, and clinical guidelines vary by region and institution. Always verify current prescribing information, institutional protocols, and patient-specific factors with an official drug database or the prescribing clinician before administration.
